Rationale and design of the Kanyini guidelines adherence with the polypill (Kanyini-GAP) study: a randomised controlled trial of a polypill-based strategy amongst Indigenous and non Indigenous people at high cardiovascular risk
Autor: | Hueiming, Liu, Anushka, Patel, Alex, Brown, Sandra, Eades, Noel, Hayman, Stephen, Jan, Ian, Ring, Greg, Stewart, Andrew, Tonkin, Tarun, Weeramanthri, Vicki, Wade, Anthony, Rodgers, Tim, Usherwood, Bruce, Neal, David, Peiris, Hugh, Burke, Christopher, Reid, Alan, Cass, John, Meaney |
---|---|
Přispěvatelé: | Liu, Hueiming, Patel, Anushka, Brown, Alex, Eades, Sandra J, Hayman, Neol, Jan, Stephen, Ring, Ian, Stewart, Gregory, Tonkin, Andrew, Weeramanthri, Tarun, Wade, Victoria, Rodgers, Anthony, Usherwood, Tim, Neal, Bruce, Peiris, David, Burke, Hugh, Reid, Christopher, Cass, Alan |
Jazyk: | angličtina |
Předmět: |
medicine.medical_specialty
Native Hawaiian or Other Pacific Islander Statin medicine.drug_class Cost-Benefit Analysis Alternative medicine 030204 cardiovascular system & hematology Indigenous Medication Adherence law.invention Study Protocol 03 medical and health sciences 0302 clinical medicine Randomized controlled trial law medicine Humans Prospective Studies 030212 general & internal medicine Polypill Intensive care medicine Aspirin business.industry lcsh:Public aspects of medicine Public Health Environmental and Occupational Health lcsh:RA1-1270 3. Good health Clinical trial Drug Combinations Cardiovascular Diseases Physical therapy Guideline Adherence New South Wales Biostatistics business medicine.drug |
Zdroj: | BMC Public Health, Vol 10, Iss 1, p 458 (2010) BMC Public Health |
ISSN: | 1471-2458 |
DOI: | 10.1186/1471-2458-10-458 |
Popis: | Background The Kanyini Guidelines Adherence with the Polypill (Kanyini-GAP) Study aims to examine whether a polypill-based strategy (using a single capsule containing aspirin, a statin and two blood pressure-lowering agents) amongst Indigenous and non-Indigenous people at high risk of experiencing a cardiovascular event will improve adherence to guideline-indicated therapies, and lower blood pressure and cholesterol levels. Methods/Design The study is an open, randomised, controlled, multi-centre trial involving 1000 participants at high risk of cardiovascular events recruited from mainstream general practices and Aboriginal Medical Services, followed for an average of 18 months. The participants will be randomised to one of two versions of the polypill, the version chosen by the treating health professional according to clinical features of the patient, or to usual care. The primary study outcomes will be changes, from baseline measures, in serum cholesterol and systolic blood pressure and self-reported current use of aspirin, a statin and at least two blood pressure lowering agents. Secondary study outcomes include cardiovascular events, renal outcomes, self-reported barriers to indicated therapy, prescription of indicated therapy, occurrence of serious adverse events and changes in quality-of-life. The trial will be supplemented by formal economic and process evaluations. Discussion The Kanyini-GAP trial will provide new evidence as to whether or not a polypill-based strategy improves adherence to effective cardiovascular medications amongst individuals in whom these treatments are indicated. Trial Registration This trial is registered with the Australian New Zealand Clinical Trial Registry ACTRN126080005833347. |
Databáze: | OpenAIRE |
Externí odkaz: |